Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 4.1 Specimen Class a Common Stock Certificate
- 5.1 Opinion of White & Case LLP As to the Validity of the Securities Being Registered
- 10.34 Exclusive License Agreement by and Between Eqrx, Inc. and G1 Therapeutics, Inc. Dated June 22, 2020
- 10.35 License Agreement by and Between Eqrx, Inc. and Cstone Pharmaceuticals Dated October 26, 2020
- 23.2 Consent of Ernst & Young LLP
- 99.1 Form of Preliminary Proxy Card
- 99.11 Consent of Houlihan Loukey Capital, Inc
- Download Excel data file
- View Excel data file
Associated filings
- 2 Dec 21 EFFECT Notice of effectiveness
- 1 Dec 21 424B3 Prospectus supplement
- 30 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
29 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 Aug 21 S-4 Registration of securities issued in business combination transactions
EQRX similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated August 25, 2021, with respect to the consolidated financial statements of EQRx, Inc. included in the Proxy Statement of CM Life Sciences III Inc. that is made a part of Amendment No. 2 to the Registration Statement (Form S-4 No. 333-259054) and Prospectus of CM Life Sciences III Inc. for the registration of 415,000,000 shares of its common stock.
/s/ Ernst & Young LLP
Boston, Massachusetts
October 29, 2021